Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 10/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247291 | 0.86 | AKR1B1 (0.56) | KDM4EGPR35MAPTGAAMAOB | |
| SCHEMBL4249060 | 0.85 | GPR35 (0.42) | KDM4EGPR35MAPTGAAMAOB | |
| SCHEMBL4254725 | 0.85 | AKR1B1 (0.57) | KDM4EGPR35MAPTGAAMAOB | |
| SCHEMBL8115765 | 0.83 | ALDH1A1 (0.57) | KDM4EGPR35MAPTGAALMNA | |
| SCHEMBL8119628 | 0.83 | KDM4E (0.50) | KDM4EGPR35MAPTGAAMAOB | |
| SCHEMBL4250588 | 0.83 | MAOB (0.69) | KDM4EGPR35MAPTMAOBATM | |
| SCHEMBL4252013 | 0.83 | MAOB (0.49) | KDM4EGPR35MAPTGAAMAOB | |
| SCHEMBL4253451 | 0.82 | GPR35 (0.61) | KDM4EGPR35ALDH1A1 | |
| SCHEMBL28290283 | 0.82 | GPR35 (0.47) | KDM4EGPR35LMNAKMT2AALDH1A1 | |
| SCHEMBL4252681 | 0.82 | MAOB (0.60) | KDM4EGPR35MAPTGAAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101497571-B | Process for producing chromone compound | SUMITOMO CO LTD | 2012-07-04 | — | — | CN | disclosed |
| CN-1911896-B | Process for producing benzopyrone compound | SUMITOMO CHEMICAL CO | 2010-09-15 | — | — | CN | disclosed |
| EP-2105431-A1 | Process for Producing Chromone Compound | Sumitomo Chemical Company, Limited (JP) | 2009-09-30 | — | — | EP | disclosed |
| EP-2105432-A1 | Process for Producing Chromone Compound | Sumitomo Chemical Company, Limited (JP) | 2009-09-30 | — | — | EP | disclosed |
| CN-101497571-A | Process for producing chromone compound | SUMITOMO CHEMICAL CO (JP) | 2009-08-05 | — | — | CN | disclosed |
| CN-100509751-C | Process for producing benzopyranone compound | SUMITOMO CHEMICAL CO (JP) | 2009-07-08 | — | — | CN | disclosed |
| EP-1867626-A2 | Process for producing chromone compound | Sumitomo Chemical Company, Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
| CN-1911896-A | Process for producing chromone compound | SUMITOMO CHEMICAL CO (JP) | 2007-02-14 | — | — | CN | disclosed |
| US-20060217565-A1 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-09-28 | — | — | US | disclosed |
| US-7094914-B2 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-22 | — | — | US | disclosed |
| CN-1649824-A | Process for producing benzopyranone compound | SUMITOMO CHEMICAL CO (JP) | 2005-08-03 | — | — | CN | disclosed |
| US-20050085664-A1 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LMITED (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1479667-A1 | PROCESS FOR PRODUCING CHROMONE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085664-A1 | Process for producing chromone compound | ENY2, CDY1; CDY1B, CDYL | KDM4E 978/4885GPR35 2693/4885MAPT 4765/4885 |
| US-20060217565-A1 | Process for producing chromone compound | ENY2, CDY1; CDY1B, CDYL | KDM4E 978/4885GPR35 2693/4885MAPT 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.